12 April 2018, Paris, France: Surveillance for hepatocellular carcinoma (HCC) by ultrasound is likely to be cost effective in patients with hepatitis C-related liver cirrhosis after they have achieved a sustained virological response (SVR) to direct-acting antiviral agents (DAAs), according to the results of a Canadian study presented today. The study also found that screening is very unlikely to be cost effective in patients with advanced liver fibrosis but without evidence of cirrhosis (e.g. METAVIR stage F3), challenging current clinical practice guidelines.
Hepatitis C virus (HCV) infection is a major cause of HCC worldwide, and although the HCC risk is reduced substantially after SVR, it is not eliminated entirely.1 Surveillance for HCC among people with HCV infection is considered to be cost effective if the risk of HCC exceeds 1.5% per year prior to SVR; however, after achieving SVR, the values may differ because the risk of liver failure is substantially reduced. 1,10 Current HCV management guidelines recommend biannual surveillance for HCC for an indefinite period in all patients with stage 3 fibrosis or liver cirrhosis post-SVR.11,12
The study presented today at The International Liver Congress™ 2018 in Paris, France, evaluated the cost effectiveness of biannual or annual ultrasound screening for HCC in HCV-infected patients who had achieved an SVR after DAAs. A Markov model was developed based on parameters extracted from the literature and expert opinion. Primary outcomes assessed were quality-adjusted life years (QALYs), cost and incremental cost-effectiveness ratio (ICER).
The base case for the study was all patients with advanced fibrosis (F3/F4) in whom the risk of HCC post-SVR is estimated to be 0.5% per year. With this low incidence of HCC, biannual or annual screening after DAA-induced SVR provided an additional 0.16 QALYs (ICER $84,242/QALY) and 0.15 QALYs (ICER $53,756/QALY), respectively, putting surveillance near or slightly above the usual willingness-to-pay thresholds ($50,000/QALY). Using recent data suggesting that the annual incidence of HCC in patients with HCV-related cirrhosis post-DAA-induced SVR may be as high as 1.82%,13 biannual HCC screening was found to be cost effective (ICER $40,803/QALY).
To address the challenge that cirrhosis may be difficult to diagnose, the research team also investigated the cost effectiveness of using simple thresholds for aspartate aminotransferase to platelet ratio index (APRI) and FIB4 to assess fibrosis. In contrast, a biannual screening strategy for those with a pre-treatment APRI of <2 and a corresponding annual HCC incidence of 0.093% was not cost effective (dominated with an ICER of $1,024,982/QALY), highlighting the utility of this simple test to risk stratify patients for surveillance. With a pre-treatment APRI >2, even without documented cirrhosis, the annual incidence of HCC was 0.89%, leading to an ICER of $55,916/QALY for biannual screening.
'The results of our study challenge current clinical practice guidelines by suggesting that ultrasound surveillance is very unlikely to be cost effective in patients without cirrhosis', said Dr Hooman Farhang Zangneh from the University of Toronto, Canada, who presented the study findings today. 'However, for patients with cirrhosis, even if diagnosed using only pre-treatment APRI/FIB4, biannual or annual ultrasound surveillance after DAA-induced SVR is likely to be cost effective, particularly if the risk of HCC is found to increase with age. Additional long-term follow-up data will help to identify those at higher risk of HCC post-SVR to further tailor surveillance guidelines'.
'HCC surveillance in HCV patients after sustained virological response is a matter of debate', said Prof. Markus Cornberg from the Hannover Medical School, Germany, and EASL Governing Board Member. 'This study is important because it emphasizes the importance of HCC surveillance by ultrasound in patients with cirrhosis, even if HCV has been eliminated. However, the study also challenges the need for surveillance in patients with advanced fibrosis but without cirrhosis'.
About The International Liver Congress™
This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Attending specialists present, share, debate and conclude on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. The International Liver Congress™ 2018 will take place from 11¬-15 April 2018 at the Paris Convention Centre, Paris, France.
About The European Association for the Study of the Liver (EASL)
Since its foundation in 1966, this not-for-profit organization has grown to over 4,000 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European association with international influence, and with an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
For more information, please contact the ILC Press Office at:
- Email: firstname.lastname@example.org
- Telephone: +41 (0) 22 807 29 88
Onsite location reference
Session title: Parallel session: Public health: General
Time, date and location of session: 12. April 2018, 05:00 PM - 05:15 PM, West 2
Presenter: Hooman Farhang Zangneh, Canada
Abstract: Cost-effectiveness analysis of hepatocellular carcinoma screening in hepatitis C cirrhosis after sustained viral response
8. Baumert TF, et al. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med. 2017;15(1):52.
9. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-43.
10. Bruix J, et al. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-2.
11. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2016;2017;66:153-94.
12. Jacobson IM, et al. American Gastroenterological Association Institute Clinical Practice Update-Expert review: care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis c infection. Gastroenterology. 2017;152(6):1578-87.
13. Kanwal F, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996-1005.e1.